Home | Contact
Deciphera

Mimicry of Endogenous Kinase Regulation

Kinase
 

Deciphera's kinase switch inhibitors

Distinguishing features

Controlling kinase shape- Switch inhibitors control kinase activity by regulating protein shape, mimicking how cellular kinases are naturally controlled.

New therapies in cancer- Oncogenic (cancer-causing) kinases are often mutated, such that control of kinase shape and activity is lost. Deciphera's approach restores control to such dysregulated kinases.

Solving the problems of drug resistance- Switch inhibitors retain potency against drug-resistant kinase mutations, including mutations in the gatekeeper region.

Control of kinase inhibitor selectivity profiles- Switch inhibitor strategies enable unprecedented selectivity profiles relative to other kinase inhibitor classes.

Switch inhibition of kinases is general- Deciphera has identified kinase switch inhibitors from all major kinase families, including kinases involved in metabolic diseases, inflammation, and cardiovascular deseases.

 

Development Programs


Chronic Myelogeous Leukemia (CML) Program

DCC-2036
Late-stage preclinical development

Phase 1 trials in CML scheduled for Q1 2009.

» Inhibitor of BCR-ABL and T315I BCR-ABL gatekeeper mutant, resistant to all marketed kinase inhibitors.


DCC-2157
Preclinical development

» Inhibitor of BCR-ABL and T315I BCR-ABL gatekeeper mutant, resistant to all marketed kinase inhibitors.

Gastrointestinal Stromal Tumor (GIST) program

DP-3407/DP-3429

» Inhibitor primary mutant cKIT kinase and major secondary mutant forms including V654A, D816V, D816H, T670I


Discovery Programs


BRAF kinase- Malignant melanoma/colo-rectal cancer program
Partnered with Eli Lilly and Company

DP-3346

» Inhibitor of all RAF kinase isoforms, including V600E oncogenic mutant

Solid tumor Program

DP-3590

» Inhibitor of cMET kinase

 

In the News


Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement

Eli Lilly and Company (NYSE:LLY) and privately-held Deciphera Pharmaceuticals, LLC today announced that the two companies have entered into a collaboration and worldwide licensing agreement related to Deciphera's preclinical B-Raf kinase inhibitor program for the study of potential oncology therapeutics.


The collaboration will apply Deciphera's phylomechnanics discovery platform, a unique, proprietary approach to kinase inhibitor design, together with Lilly's expertise in discovery, development and commercialization to pursue first-in-class drug candidates for a variety of cancers.

KU to lease out vacant lab space for local expansion by Deciphera Pharmaceuticals

Laboratory space temporarily vacant at the University of Kansas will soon be put to good use in a new and innovative way. Effective November 1, 2008, it will be leased for an initial 18 months to a growing, Kansas-based, biosciences company in need of space to expand its operations.


Dr. James Bristol joins Deciphera Pharmaceuticals Board of Managers

Deciphera Pharmaceuticals LLC (Lawrence, Kansas) announces the appointment of Dr. James A. Bristol to its Board of Managers.


Deciphera Pharmaceuticals, LLC
4950 Research Park Way
Lawrence, KS 66047

785-838-3767 phone
785-838-3747 fax
info@deciphera.com

Home | Senior Management | Platform | BCR-ABL | KIT | BRAF | News | Partners | Contact